Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Clark, Justin T ^a   Clark, Meredith R ^b   Shelke, Namdev B ^a   Johnson, Todd J ^a   Smith, Eric M ^a   Andreasen, Andrew K ^a   Nebeker, Joel S ^a   Fabian, Judit ^a   Friend, David R ^b   Kiser, Patrick F ^a,c  

^a University of Utah   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c Northwestern University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCEROL; LEVONORGESTREL; POLYURETHAN; TENOFOVIR; CONTRACEPTIVE AGENT; POLYETHERURETHAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG STORAGE; DRUG STRUCTURE; DRUG TISSUE LEVEL; EQUIPMENT DESIGN; FEMALE; MATHEMATICAL MODEL; NEW ZEALAND WHITE (RABBIT); NONHUMAN; SUSTAINED DRUG RELEASE; TENSILE STRENGTH; VAGINA RING; ALGORITHM; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; ELASTICITY; FEMALE CONTRACEPTIVE DEVICE; HIV INFECTIONS; HUMAN; PREGNANCY; RABBIT; THEORETICAL MODEL; TRANSMISSION; UNWANTED PREGNANCY;

ALGORITHMS; ANIMALS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; DRUG DELIVERY SYSTEMS; ELASTICITY; FEMALE; HIV INFECTIONS; HUMANS; LEVONORGESTREL; MODELS, THEORETICAL; POLYURETHANES; PREGNANCY; PREGNANCY, UNWANTED; RABBITS; TENSILE STRENGTH;

EID: 84897137511     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088509     Document Type: Article

References (46)

1. Folkers GK, Fauci AS (2010) Controlling and ultimately ending the HIV/AIDS pandemic: a feasible goal. JAMA 304: 350-351.
2. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367: 399-410.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 329: 1168-1174.
4. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, et al. (2013) Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003) (Paper 26LB). 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, Georgia.
5. Heneine W, Kashuba A (2012) HIV prevention by oral preexposure prophylaxis. Cold Spring Harbor Perspect Med 2: a007419/007411-a007419/007413.
6. Shattock RJ, Rosenberg Z (2012) Microbicides: topical prevention against HIV. Cold Spring Harbor Perspect Med 2: a007385/007381-a007385/007317.
7. Friend DR, Kiser PF (2013) Assessment of topical microbicides to prevent HIV-1 transmission: Concepts, testing, lessons learned. Antiviral Res 99: 391-400.
8. Hankins CA, Dybul MR (2013) The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr Opin HIV AIDS 8: 50-58.
9. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR (2012) Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26: F13-19.
10. Dobard C, Sharma S, Martin A, Pau CP, Holder A, et al. (2012) Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol 86: 718-725.
11. Singer R, Mawson P, Derby N, Rodriguez A, Kizima L, et al. (2012) An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med 4: 150ra123.
12. Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PMM, et al. (2013) An intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal SHIV challenges. Proc Natl Acad Sci 110: 16145-16150.
13. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, et al. (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372: 1977-1987.
14. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, et al. (2002) Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 24: 302-316. (Pubitemid 34208424)
15. Kruk ME, Schwalbe N (2006) The relation between intermittent dosing and adherence: preliminary insights. Clin Ther 28: 1989-1995. (Pubitemid 46215746)
16. Andrews C, Gettie A, Russell-Lodrigue K, Moss L, Mohri H, et al. (2013) Long-acting parenteral formulation of GSK1265744 protects macaques against repeated intrarectal challenges with SHIV (Paper 24LB). 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, Georgia.
17. Kiser PF, Johnson TJ, Clark JT (2012) State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev 14: 62-77.
18. Fetherston SM, Malcolm RK, Woolfson AD (2010) Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides. Therapeutic Delivery 1: 785-802.
19. Malcolm RK, Fetherston SM (2013) Delivering on MPTs: addressing the needs, rising to the challenges and making the opportunities. Contraception 88: 321-325.
20. Friend DR (2012) Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission. Expert Opin Drug Delivery 9: 417-427.
21. Friend DR (2011) Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections. Drug Delivery Transl Res 1: 185-193.
22. Wertheimer AI (2013) The economics of polypharmacology: fixed dose combinations and drug cocktails. Curr Med Chem 20: 1635-1638.
23. Connor J, Rafter N, Rodgers A (2004) Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 82: 935-939. (Pubitemid 40065162)
24. Koetsawang S, Ji G, Krishna U, Cuadros A, Dhall GI, et al. (1990) Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 41: 105-124.
25. Johnson TJ, Clark MR, Albright TH, Nebeker JS, Tuitupou AL, et al. (2012) A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother 56: 6272-6283.
26. Clark JT, Johnson TJ, Clark MR, Nebeker JS, Fabian J, et al. (2012) Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. J Control Release 163: 240-248.
27. Clark MR, Johnson TJ, McCabe RT, Clark JT, Tuitupou A, et al. (2012) A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J Pharm Sci 101: 576-587.
28. Malcolm K, Woolfson D, Russell J, Tallon P, McAuley L, et al. (2003) Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. Journal of Controlled Release 90: 217-225. (Pubitemid 36694965)
29. Nel A, Smythe S, Young K, Malcolm K, McCoy C, et al. (2009) Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. Journal of acquired immune deficiency syndromes 51: 416-423.
30. Johnson TJ, Srinivasan P, Albright TH, Watson-Buckheit K, Rabe L, et al. (2012) Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 56: 1291-1299.
31. Johnson TJ, Gupta KM, Fabian J, Albright TH, Kiser PF (2010) Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 39: 203-212.
32. Mesquita PM, Rastogi R, Segarra TJ, Teller RS, Torres NM, et al. (2012) Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother 67: 1730-1738.
33. Gupta KM, Pearce SM, Poursaid AE, Aliyar HA, Tresco PA, et al. (2008) Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci 97: 4228-4239.
34. van Laarhoven JA, Kruft MA, Vromans H (2002) In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. Int J Pharm 232: 163-173. (Pubitemid 34076762)
35. Saltzman WM (2001) Engineering principles for drug therapy. New York: Oxford University Press.
36. van Laarhoven JA, Kruft MA, Vromans H (2002) Effect of supersaturation and crystallization phenomena on the release properties of a controlled release device based on EVA copolymer. J Control Release 82: 309-317. (Pubitemid 34880186)
37. Siepmann J, Siepmann F (2008) Mathematical modeling of drug delivery. Int J Pharm 364: 328-343.
38. Helbling IM, Luna JA, Cabrera MI (2011) Mathematical modeling of drug delivery from torus-shaped single-layer devices. J Control Release 149: 258-263.
39. Vergnaud J (1993) Controlled Drug Release of Oral Dosage Forms. Boca Raton: CRC Press.
40. Siepmann J, Siepmann F (2012) Modeling of diffusion controlled drug delivery. J Control Release 161: 351-362.
41. Clark MR, Kiser PF, Loxley A, McConville C, Malcolm RK, et al. (2011) Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices. Drug Delivery and Translational Research 1: 238-246.
42. Szycher M (1985) Extrudable Polyurethane for Prothetic Devices Prepared from a Diisocyanate, a Polytetramethylene Ehter Polyol, and 1,4-Butane Diol. United States Patent 4,523,005.
43. Elabd YA, Sloan JM, Tan NB, Barbari TA (2001) Effect of Penetrant-Polymer Interactions on Molecular Diffusion in Conformational Isomers of a Heterogeneous Polymer. Macromolecules 34: 6268-6273. (Pubitemid 34217137)
44. Kiser PF, Johnson TJ, Clark JT, Shelke N, Rastogi R (2013) Intravaginal Devices for Drug Delivery. WO Patent Application PCT/US2012/047649.
45. Rose S, Chaudhari A, Peterson CM (2009) Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception. Adv Drug Deliv Rev 61: 808-812.
46. Dusterberg B, Humpel M, Speck U (1981) Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys. Contraception 24: 673-683. Development Development